BCP
PBYI icon

Berylson Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Berylson Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24,800
Closed -$2.45M – 21
2017
Q4 		$2.45M Buy
+24,800
New +$2.78M 3.77% 12

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Berylson Capital Partners's PBYI Position: Q1 2018 in Review

Berylson Capital Partners sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 24,800 shares — an estimated $2.45M sold.

Berylson Capital Partners first reported a position in PBYI in Q4 2017 and held it in 1 quarter. The position peaked at $2.45M in Q4 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Berylson Capital Partners reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Berylson Capital Partners sold 24,800 Puma Biotechnology shares in Q1 2018, an estimated $2.45M.
  • Berylson Capital Partners first reported a position in Puma Biotechnology in Q4 2017 and held it in 1 quarter.
  • Berylson Capital Partners's Puma Biotechnology position peaked at $2.45M in Q4 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Berylson Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.